Lonza, founded in 1897 in the Swiss Alps, is one of the world’s largest and most established contract development and manufacturing organizations (CDMOs) serving the healthcare industry. With over 18,500 employees across more than 30 global sites, Lonza partners with biotechs and pharmaceutical companies to develop and manufacture innovative therapies—from early-stage development through to commercial production.

As a pioneer in the CDMO space, Lonza operates through three synergistic business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Its offering includes a wide range of technologies such as mammalian biologics, small molecules, HPAPIs, bioconjugates, mRNA, microbial platforms, and cell and gene therapies. With its integrated approach, Lonza supports the full therapeutic lifecycle, helping customers bring life-saving and life-enhancing treatments to patients worldwide.